Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 4, 1996, Pages 532-538

  Maggi, Elena ^a   Marchesi, Eugenia ^a   Covini, Donatella ^a   Negro, Claudia ^a   Perani, Guido ^a   Bellomo, Giorgio ^b,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Carvedilol; Hypertension; Low density lipoprotein; Oxidation

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; LIPID; LOW DENSITY LIPOPROTEIN; VASODILATOR AGENT;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; AUTOANTIBODIES; CARBAZOLES; FEMALE; HUMANS; HYPERTENSION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROPANOLAMINES; VASODILATOR AGENTS; VITAMIN E;

EID: 0029960787     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199604000-00012     Document Type: Article

References (41)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-24.
2. Berliner JA, Haberland ME. The role of oxidized low density lipoprotein in atherogenesis. Curr Opin Lipidol 1993;4: 373-81.
3. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994;344:793-5.
4. Avogaro P, Bittolo BG, Cazzolato G: Presence of a modified low-density lipoprotein in humans. Arteriosclerosis 1988;8: 79-87.
5. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al. Low-density lipoprotein undergoes oxidative modifications in vivo. Proc Natl Acad Sci USA 1989;86:1372-6.
6. Rosenfeld ME, Palinski W, Yla-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990; 10:336-49.
7. Jurgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein (a). Arterioscl Thromb 1993;13:1689-99.
8. Berliner JA, Territo M, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyle endothelial interactions. J Clin Invest 1990;85:1260-6.
9. Cushing SD, Berliner JA, Valentine AJ, et al. Minimally modified LDL induces MCP-1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87: 5134-8.
10. Fogelman AM, Shechter I, Saeger J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980;77: 2214-8.
11. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipids. J Lipid Res 1983;24:1070-6.
12. Chisolm GM, Ma G, Irwin KC, et al. 7b-Hydroperoxycholest-5-en-3b-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc Natl Acad Sci USA 1994;91:11452-6.
13. Lavy A, Brook GJ, Dankner G, Amotz AB, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 1991;40: 794-9.
14. Maggi E, Marchesi E, Ravetta V, Falaschi F, Finardi G, Bellomo G. Low density lipoprotein oxidation in essential hypertension. J Hypertens 1993;11:1103-11.
15. Maggi E, Chiesa R, Melissano G, et al. LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994;14:1892-9.
16. Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876-83.
17. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low density lipoproteins in NIDDM. Diabetes 1995;44:60-6.
18. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G. Presence of autoantibodies against oxidatively modified low density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low density lipoprotein oxidation. J Hypertens 1995;13:129-38.
19. Keidar S, Kaplan M, Shapira C, Brooke JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994;107:71-84.
20. Jameson M, Dai FX, Lusher T, Skopec J, Diederich A, Diederich D. Endothelium derived contracting factors in resistance arteries of young spontaneously hypertensive rats before development of overt hypertension. Hypertension 1993;21:280-8.
21. Kumar KW, Das UM. Are free radicals involved in the pathobiology of human essential hypertension? Free Rad Res Commun 1993;19:59-66.
22. Hunter GC, Dubick MA, Keen CL, Eskelson CD. Effects of hypertension on aortic antioxidant status in human abdominal aneurysmal and occlusive disease. Proc Soc Exp Biol Med 1991;196:273-9.
23. Henry DP. Antiperoxidative action of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol 1991;18 (suppl 1):S6-10.
24. Croft KD, Dimmitt SB, Moulton C, Beilin LJ. Low density lipoprotein composition and oxidizability in coronary disease - apparent favourable effect of beta blockers. Atherosclerosis 1992;97:123-30.
25. Godfrey EG, Stewart J, Dargie HJ, et al. Effects of ACE inhibitors on oxidation of human low density lipoprotein. Br J Clin Pharmacol 1994;37:63-6.
26. Yue TL, McKenna PJ, Lysko PG, Ruffolo RR, Feuerstein GZ. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992;97:209-16.
27. Yue TL, Wang X, Gu JL, Ruffolo RR, Feuerstein GZ. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995;273: 1442-9.
28. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun 1989;6:67-75.
29. Dieber-Rotheneder M, Phul H, Waeg G, Striegl G, Esterbauer H. Effect of oral supplementation with D-alpha-tocopherol on the vitamin E content of human low density lipoproteins and its oxidation resistance. J Lipid Res 1991;32:1325-32.
30. Bellomo G, Maggi E, Palladini G, Taddei F, Seccia M, Finardi G. Diagnostic criteria in investigating LDL oxidation. In: Bellomo G, Finardi G, Maggi E, Rice-Evans C, eds. Free radicals, lipoprotein oxidation and atherosclerosis. London: Richelieu Press, 1995:263-86.
31. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med 1992;13:341-90.
32. Jurgens G, Ashy A, Esterbauer H. Detection of new epitopes formed upon oxidation of low density lipoprotein, lipoprotein (a) and very low density lipoprotein. Biochem J 1990;265:605-8.
33. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263:92-8.
34. Feuerstein GZ, Hamburger SA, Smith EF, Bril A, Ruffolo RR. Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992;19 (suppl 1):S138-41.
35. Ruffolo RR, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38:S82-8.
36. Bonanome A, Pagan A, Biffanti S, et al. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoprotein to oxidative modification. Arterioscler Thromb 1992;12:529-33.
37. Elinder LS, Hadell K, Johansson J, et al. Probucol treatment decreases serum concentrations of diet derived antioxidants. Arterioscler Thromb Vasc Biol 1995;15:1057-63.
38. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991;88:10045-8.
39. White CR, Brock TA, Chang LY, et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994;91:1044-8.
40. Pou S, Nguyen SY, Gladwell T, Rosen GM. Does peroxynitrite generate hydroxyl radical? Biochim Biophys Acta 1995; 1244:62-8.
41. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoprotein cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 1990;86:75-9.